Streptococcus dysgalactiae subsp. equisimilis

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Streptococcus dysgalactiae subsp. equisimilis is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, coccus bacterium. It has been detected in at least 1 gut microbiome compilation study or metastudy. The DNA G+C content is 38.1-40.2%. Streptococcus dysgalactiae subsp. equisimilis is likely to be transient and not a long-term gut coloniser. (Whiley2011Bergey)



  • This organism has been recovered from human respiratory tracts and vaginas. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread (notes: human and animal pathogen). Pathogenicity status unknown, or very unlikely to be pathogenic. Likely to be transient and not a long-term gut commensal.
    • GENERAL CHARACTERISTICS (Whiley2011Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; arginine;
  • ±
  • Strain-dependent hydrolysis or digestion:
  • hippurate;
  • 🧂
  • Salt tolerance:
  • doesn't tolerate 6.5% salt;
  • pH
  • Acidity tolerance:
  • doesn't tolerate pH 9.6;
  • 🌡
  • Temperature tolerance:
  • doesn't grow at 10℃; doesn't grow at 45℃; Grows optimally at 37℃.
  • H+
  • Acid from carbohydrates usually produced:
  • glucose; ribose; starch; maltose; sucrose; trehalose;
  • ±
  • Strain-dependent acid from carbs:
  • glycogen; lactose; glycerol;
  • Active enzymes:
  • alkaline phosphatase; fibrinolysin; β-galactosidase; β-glucuronidase; hyaluridonase; Leu arylamidase;
    • SPECIAL FEATURES (Whiley2011Bergey);
    Character Response
  • ✗
  • VP test:
  • not active
  • Haemolysis:
  • beta
    • RESPONSE TO ANTIBIOTICS (Brandt2009); (Goldstein2008); (Goldstein2006a); (Goldstein2006b);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin-sulbactam; doripenem; ertapenem; imipenem; meropenem; penicillin; piperacillin-tazobactam;
  • Cephalosporins:
  • cefepime; cefotaxime; cefotetan; cefoxitin; ceftazidime;
  • Quinolines:
  • levofloxacin; moxifloxacin;
  • Heterocycles:
  • trimethoprim-sulfamethoxazole;
  • Vancomycins:
  • vancomycin; dalbavancin;
  • Miscellaneous antibiotics:
  • clindamycin; daptomycin; linezolid;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Bacilli Order:  Lactobacillales Family:  Streptococcaceae Genus:  Streptococcus Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Coccus
    Health:  Unknown
    Source:  human respiratory tracts and vaginas
    DNA G+C(%):  38.1-40.2
    Opt. T:  37℃
    Low T(℃):  10(neg)
    High T(℃):  45(neg)
    NaCl >6%:  6.5(neg)
    pH >8:  9.6(neg)
    		Aesculin:  d(+) Starch:  neg Arginine:  + Hippurate:  d
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Glucose:  + Ribose:  + Lactose:  d Maltose:  + Sucrose:  + Trehalose:  + Glycogen:  d Inulin:  neg Starch:  + Glycerol:  d Mannitol:  neg Sorbitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg Fibrinolysin:  + Hyaluridonase:  + α-Galactosidase:  neg β-Galactosidase:  + β-Glucuronidase:  + LeuAA:  + PyrogluAA:  neg AlkalineP:  +
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.06)
    amp-sulb:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03)
    penicillin:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.06)
    piper-taz:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.125–0.125)
    doripenem:  S(MIC50): 0.015, MIC90: 0.015, RNG: (0.015)
    ertapenem:  S(≤0.25/≤0.25)
    imipenem:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.06)
    meropenem:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.06)
    cefepime:  S(MIC50): 0.015, MIC90: 0.03, RNG: (0.015–0.03)
    cefotaxime:  S(MIC50): 0.015, MIC90: 0.015, RNG: (≤0.015)
    cefotetan:  S(MIC50): 2, MIC90: 2, RNG: (1–4)
    cefoxitin:  S(MIC50): 1, MIC90: 1, RNG: (0.5–1)
    ceftazidime:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.125–0.25)
    linezolid:  S(MIC50): 2, MIC90: 2, RNG: (1–4)
    levofloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–8)
    moxifloxacin:  S(≤0.25/0.5)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    dalbavancin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.016–0.125)
    vancomycin:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.125–0.5)
    SXT:  S(≤0.5/≤0.5)
    clindamycin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.06–8)
    daptomycin:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.25)

    References

    SPECIFIC REFERENCES FOR STREPTOCOCCUS DYSGALACTIAE SUBSP. EQUISIMILIS
  • Brandt2009 - Human infections due to Streptococcus dysgalactiae subspecies equisimilis.
  • Whiley2011Bergey - Bergey's manual of systematic bacteriology. Vol. 3, The Firmicutes. Family Streptococcaceae, Genus I. Streptococcus
  • Vandamme1996c - Taxonomic study of lancefield streptococcal groups C, G, and L (Streptococcus dysgalactiae) and proposal of S. dysgalactiae subsp. equisimilis subsp. nov.
  • Goldstein2008 - In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
  • Goldstein2006a - In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
  • Goldstein2006b - In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR STREPTOCOCCUS DYSGALACTIAE SUBSP. EQUISIMILIS
  • Finegold1977 - Fecal microbial flora in Seventh Day Adventist populations and control subjects.
  • ...............................
    • Added: March 18, 2022